# Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT00408629** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 518 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00408629
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2011-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408629, "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00408629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*